Oral
Clostridioides difficile infection
Adult: As alternative oral treatment (powder for inj/infusion may be used to prepare the oral solution) for antibiotic-associated colitis or diarrhoea caused by Clostridioides difficile: 100-200 mg bid for 7-14 days. Dosage recommendation may vary among individual products or between countries (refer to local detailed product guidelines).
Reconstitution: Powder for solution for inj/infusion or oral solution: Reconstitute a vial labelled as containing 200 mg or 400 mg with 3.14 mL of sterile water for inj to prepare a 200 mg/3mL or 400 mg/3mL concentration, respectively. Rotate slowly to dissolve the powder. Do not shake. If foam develops, allow the solution to stand for 15 minutes. Further dilute the reconstituted solution with a suitable IV fluid for infusion (e.g. NaCl 0.9% solution, dextrose 5% inj). Refer to local detailed product guidelines for further compatible infusion fluids. Reconstituted solution may be injected directly, further diluted for IV infusion or peritoneal dialysis solution, or prepared for oral administration.
Intravenous
Continuous ambulatory peritoneal dialysis (CAPD)-associated peritonitis
Adult: Initially, 6 mg/kg as a single loading dose given via IV. Maintenance (teicoplanin is added to the peritoneal dialysis fluid): 20 mg/L is added in each bag of dialysis solution in the 1st week, followed by 20 mg/L in alternate bags in the 2nd week, and then 20 mg/L in the overnight bag in the 3rd week.
Reconstitution: Powder for solution for inj/infusion or oral solution: Reconstitute a vial labelled as containing 200 mg or 400 mg with 3.14 mL of sterile water for inj to prepare a 200 mg/3mL or 400 mg/3mL concentration, respectively. Rotate slowly to dissolve the powder. Do not shake. If foam develops, allow the solution to stand for 15 minutes. Further dilute the reconstituted solution with a suitable IV fluid for infusion (e.g. NaCl 0.9% solution, dextrose 5% inj). Refer to local detailed product guidelines for further compatible infusion fluids. Reconstituted solution may be injected directly, further diluted for IV infusion or peritoneal dialysis solution, or prepared for oral administration.
Incompatibility: Incompatible with aminoglycoside solution when used for inj or infusion. However, teicoplanin and aminoglycoside solutions are compatible in dialysis fluid and may be used for CAPD-related peritonitis.
Parenteral
Complicated urinary tract infections
Adult: In combination with other antibacterial agents: Loading dose: 6 mg/kg 12 hourly for 3 doses. Maintenance: 6 mg/kg once daily, may be adjusted based on the desired target trough concentrations (refer to detailed product guidelines). All doses may be given via IV inj over 3-5 minutes, IV infusion over 30 minutes or via IM inj. Treatment duration must be adjusted according to the type and severity of infection and the patient's clinical response. Max treatment duration: 4 months.
Child: ≤2 months Loading dose: 16 mg/kg as a single dose on Day 1. Maintenance: 8 mg/kg once daily starting on Day 2. Doses are given only via IV infusion over 30 minutes; 2 months to 12 years Loading dose: 10 mg/kg 12 hourly for 3 doses. Maintenance: 6-10 mg/kg once daily. Doses are administered via IV inj over 3-5 minutes or IV infusion over 30 minutes; >12 years Same as adult dose.
Renal impairment: Initially, administer the usual IV/IM doses for the 1st 3 days or 4 days of therapy. Thereafter, adjust the dose based on CrCl starting only on the 4th day or 5th day of treatment. Recommended day for the start of dose adjustments may vary between countries (refer to local guidelines). Patients undergoing dialysis: Reduce the maintenance dose to 1/3 of the usual dose (either by administering the maintenance dose every 3 days or by giving 1/3 of the maintenance dose once daily).
CrCl (ml/min) | Dosage Recommendation |
<30 | Reduce maintenance dose to 1/3 of the usual dose (either by administering the maintenance dose every 3 days or by giving 1/3 of the maintenance dose once daily) |
30-80 | Reduce the maintenance dose to half of the usual dose (either by administering the maintenance dose every 2 days or by giving half of the maintenance dose once daily). |
Reconstitution: Powder for solution for inj/infusion or oral solution: Reconstitute a vial labelled as containing 200 mg or 400 mg with 3.14 mL of sterile water for inj to prepare a 200 mg/3mL or 400 mg/3mL concentration, respectively. Rotate slowly to dissolve the powder. Do not shake. If foam develops, allow the solution to stand for 15 minutes. Further dilute the reconstituted solution with a suitable IV fluid for infusion (e.g. NaCl 0.9% solution, dextrose 5% inj). Refer to local detailed product guidelines for further compatible infusion fluids. Reconstituted solution may be injected directly, further diluted for IV infusion or peritoneal dialysis solution, or prepared for oral administration.
Incompatibility: Incompatible with aminoglycoside solution when used for inj or infusion. However, teicoplanin and aminoglycoside solutions are compatible in dialysis fluid and may be used for CAPD-related peritonitis.
Parenteral
Community-acquired pneumonia
Adult: In combination with other antibacterial agents: Loading dose: 6 mg/kg 12 hourly for 3 doses. Maintenance: 6 mg/kg once daily, may be adjusted based on the desired target trough concentrations (refer to detailed product guidelines). All doses may be given via IV inj over 3-5 minutes, IV infusion over 30 minutes or via IM inj. Treatment duration must be adjusted according to the type and severity of infection and the patient's clinical response. Max treatment duration: 4 months.
Child: ≤2 months Loading dose: 16 mg/kg as a single dose on Day 1. Maintenance: 8 mg/kg once daily starting on Day 2. Doses are given only via IV infusion over 30 minutes; 2 months to 12 years Loading dose: 10 mg/kg 12 hourly for 3 doses. Maintenance: 6-10 mg/kg once daily. Doses are administered via IV inj over 3-5 minutes or IV infusion over 30 minutes; >12 years Same as adult dose.
Renal impairment: Initially, administer the usual IV/IM doses for the 1st 3 days or 4 days of therapy. Thereafter, adjust the dose based on CrCl starting only on the 4th day or 5th day of treatment. Recommended day for the start of dose adjustments may vary between countries (refer to local guidelines). Patients undergoing dialysis: Reduce the maintenance dose to 1/3 of the usual dose (either by administering the maintenance dose every 3 days or by giving 1/3 of the maintenance dose once daily).
CrCl (ml/min) | Dosage Recommendation |
<30 | Reduce maintenance dose to 1/3 of the usual dose (either by administering the maintenance dose every 3 days or by giving 1/3 of the maintenance dose once daily) |
30-80 | Reduce the maintenance dose to half of the usual dose (either by administering the maintenance dose every 2 days or by giving half of the maintenance dose once daily). |
Reconstitution: Powder for solution for inj/infusion or oral solution: Reconstitute a vial labelled as containing 200 mg or 400 mg with 3.14 mL of sterile water for inj to prepare a 200 mg/3mL or 400 mg/3mL concentration, respectively. Rotate slowly to dissolve the powder. Do not shake. If foam develops, allow the solution to stand for 15 minutes. Further dilute the reconstituted solution with a suitable IV fluid for infusion (e.g. NaCl 0.9% solution, dextrose 5% inj). Refer to local detailed product guidelines for further compatible infusion fluids. Reconstituted solution may be injected directly, further diluted for IV infusion or peritoneal dialysis solution, or prepared for oral administration.
Incompatibility: Incompatible with aminoglycoside solution when used for inj or infusion. However, teicoplanin and aminoglycoside solutions are compatible in dialysis fluid and may be used for CAPD-related peritonitis.
Parenteral
Complicated skin and soft tissue infections
Adult: In combination with other antibacterial agents: Loading dose: 6 mg/kg 12 hourly for 3 doses. Maintenance: 6 mg/kg once daily, may be adjusted based on the desired target trough concentrations (refer to detailed product guidelines). All doses may be given via IV inj over 3-5 minutes, IV infusion over 30 minutes or via IM inj. Treatment duration must be adjusted according to the type and severity of infection and the patient's clinical response. Max treatment duration: 4 months.
Child: ≤2 months Loading dose: 16 mg/kg as a single dose on Day 1. Maintenance: 8 mg/kg once daily starting on Day 2. Doses are given only via IV infusion over 30 minutes; 2 months to 12 years Loading dose: 10 mg/kg 12 hourly for 3 doses. Maintenance: 6-10 mg/kg once daily. Doses are administered via IV inj over 3-5 minutes or IV infusion over 30 minutes; >12 years Same as adult dose.
Renal impairment: Initially, administer the usual IV/IM doses for the 1st 3 days or 4 days of therapy. Thereafter, adjust the dose based on CrCl starting only on the 4th day or 5th day of treatment. Recommended day for the start of dose adjustments may vary between countries (refer to local guidelines). Patients undergoing dialysis: Reduce the maintenance dose to 1/3 of the usual dose (either by administering the maintenance dose every 3 days or by giving 1/3 of the maintenance dose once daily).
CrCl (ml/min) | Dosage Recommendation |
<30 | Reduce maintenance dose to 1/3 of the usual dose (either by administering the maintenance dose every 3 days or by giving 1/3 of the maintenance dose once daily) |
30-80 | Reduce the maintenance dose to half of the usual dose (either by administering the maintenance dose every 2 days or by giving half of the maintenance dose once daily). |
Reconstitution: Powder for solution for inj/infusion or oral solution: Reconstitute a vial labelled as containing 200 mg or 400 mg with 3.14 mL of sterile water for inj to prepare a 200 mg/3mL or 400 mg/3mL concentration, respectively. Rotate slowly to dissolve the powder. Do not shake. If foam develops, allow the solution to stand for 15 minutes. Further dilute the reconstituted solution with a suitable IV fluid for infusion (e.g. NaCl 0.9% solution, dextrose 5% inj). Refer to local detailed product guidelines for further compatible infusion fluids. Reconstituted solution may be injected directly, further diluted for IV infusion or peritoneal dialysis solution, or prepared for oral administration.
Incompatibility: Incompatible with aminoglycoside solution when used for inj or infusion. However, teicoplanin and aminoglycoside solutions are compatible in dialysis fluid and may be used for CAPD-related peritonitis.
Parenteral
Hospital-acquired pneumonia
Adult: In combination with other antibacterial agents: Loading dose: 6 mg/kg 12 hourly for 3 doses. Maintenance: 6 mg/kg once daily, may be adjusted based on the desired target trough concentrations (refer to detailed product guidelines). All doses may be given via IV inj over 3-5 minutes, IV infusion over 30 minutes or via IM inj. Treatment duration must be adjusted according to the type and severity of infection and the patient's clinical response. Max treatment duration: 4 months.
Child: ≤2 months Loading dose: 16 mg/kg as a single dose on Day 1. Maintenance: 8 mg/kg once daily starting on Day 2. Doses are given only via IV infusion over 30 minutes; 2 months to 12 years Loading dose: 10 mg/kg 12 hourly for 3 doses. Maintenance: 6-10 mg/kg once daily. Doses are administered via IV inj over 3-5 minutes or IV infusion over 30 minutes; >12 years Same as adult dose.
Renal impairment: Initially, administer the usual IV/IM doses for the 1st 3 days or 4 days of therapy. Thereafter, adjust the dose based on CrCl starting only on the 4th day or 5th day of treatment. Recommended day for the start of dose adjustments may vary between countries (refer to local guidelines). Patients undergoing dialysis: Reduce the maintenance dose to 1/3 of the usual dose (either by administering the maintenance dose every 3 days or by giving 1/3 of the maintenance dose once daily).
CrCl (ml/min) | Dosage Recommendation |
<30 | Reduce maintenance dose to 1/3 of the usual dose (either by administering the maintenance dose every 3 days or by giving 1/3 of the maintenance dose once daily) |
30-80 | Reduce the maintenance dose to half of the usual dose (either by administering the maintenance dose every 2 days or by giving half of the maintenance dose once daily). |
Reconstitution: Powder for solution for inj/infusion or oral solution: Reconstitute a vial labelled as containing 200 mg or 400 mg with 3.14 mL of sterile water for inj to prepare a 200 mg/3mL or 400 mg/3mL concentration, respectively. Rotate slowly to dissolve the powder. Do not shake. If foam develops, allow the solution to stand for 15 minutes. Further dilute the reconstituted solution with a suitable IV fluid for infusion (e.g. NaCl 0.9% solution, dextrose 5% inj). Refer to local detailed product guidelines for further compatible infusion fluids. Reconstituted solution may be injected directly, further diluted for IV infusion or peritoneal dialysis solution, or prepared for oral administration.
Incompatibility: Incompatible with aminoglycoside solution when used for inj or infusion. However, teicoplanin and aminoglycoside solutions are compatible in dialysis fluid and may be used for CAPD-related peritonitis.
Parenteral
Infective endocarditis
Adult: In combination with other antibacterial agents: Loading dose: 12 mg/kg 12 hourly for 3-5 doses via IV inj over 3-5 minutes or IV infusion over 30 minutes. Maintenance: 12 mg/kg once daily via IV inj over 3-5 minutes, IV infusion over 30 minutes or via IM inj; may be adjusted based on the desired target trough concentrations (refer to detailed product guidelines). Treatment duration must be adjusted according to the type and severity of infection and the patient's clinical response. Minimum treatment duration for infective endocarditis: 21 days. Max treatment duration: 4 months.
Child: ≤2 months Loading dose: 16 mg/kg as a single dose on Day 1. Maintenance: 8 mg/kg once daily starting on Day 2. Doses are given only via IV infusion over 30 minutes; 2 months to 12 years Loading dose: 10 mg/kg 12 hourly for 3 doses. Maintenance: 6-10 mg/kg once daily. Doses are administered via IV inj over 3-5 minutes or IV infusion over 30 minutes; >12 years Same as adult dose.
Renal impairment: Initially, administer the usual IV/IM doses for the 1st 3 days or 4 days of therapy. Thereafter, adjust the dose based on CrCl starting only on the 4th day or 5th day of treatment. Recommended day for the start of dose adjustments may vary between countries (refer to local guidelines). Patients undergoing haemodialysis: Reduce the maintenance dose to 1/3 of the usual dose (either by administering the maintenance dose every 3 days or by giving 1/3 of the maintenance dose once daily).
CrCl (ml/min) | Dosage Recommendation |
<30 | Reduce maintenance dose to 1/3 of the usual dose (either by administering the maintenance dose every 3 days or by giving 1/3 of the maintenance dose once daily) |
30-80 | Reduce the maintenance dose to half of the usual dose (either by administering the maintenance dose every 2 days or by giving half of the maintenance dose once daily). |
Reconstitution: Powder for solution for inj/infusion or oral solution: Reconstitute a vial labelled as containing 200 mg or 400 mg with 3.14 mL of sterile water for inj to prepare a 200 mg/3mL or 400 mg/3mL concentration, respectively. Rotate slowly to dissolve the powder. Do not shake. If foam develops, allow the solution to stand for 15 minutes. Further dilute the reconstituted solution with a suitable IV fluid for infusion (e.g. NaCl 0.9% solution, dextrose 5% inj). Refer to local detailed product guidelines for further compatible infusion fluids. Reconstituted solution may be injected directly, further diluted for IV infusion or peritoneal dialysis solution, or prepared for oral administration.
Incompatibility: Incompatible with aminoglycoside solution when used for inj or infusion. However, teicoplanin and aminoglycoside solutions are compatible in dialysis fluid and may be used for CAPD-related peritonitis.
Parenteral
Bone and joint infections
Adult: In combination with other antibacterial agents: Loading dose: 12 mg/kg 12 hourly for 3-5 doses via IV inj over 3-5 minutes or IV infusion over 30 minutes. Maintenance: 12 mg/kg once daily via IV inj over 3-5 minutes, IV infusion over 30 minutes or via IM inj; may be adjusted based on the desired target trough concentrations (refer to detailed product guidelines). Treatment duration must be adjusted according to the type and severity of infection and the patient's clinical response. Minimum treatment duration for infective endocarditis: 21 days. Max treatment duration: 4 months.
Child: ≤2 months Loading dose: 16 mg/kg as a single dose on Day 1. Maintenance: 8 mg/kg once daily starting on Day 2. Doses are given only via IV infusion over 30 minutes; 2 months to 12 years Loading dose: 10 mg/kg 12 hourly for 3 doses. Maintenance: 6-10 mg/kg once daily. Doses are administered via IV inj over 3-5 minutes or IV infusion over 30 minutes; >12 years Same as adult dose.
Renal impairment: Initially, administer the usual IV/IM doses for the 1st 3 days or 4 days of therapy. Thereafter, adjust the dose based on CrCl starting only on the 4th day or 5th day of treatment. Recommended day for the start of dose adjustments may vary between countries (refer to local guidelines). Patients undergoing haemodialysis: Reduce the maintenance dose to 1/3 of the usual dose (either by administering the maintenance dose every 3 days or by giving 1/3 of the maintenance dose once daily).
CrCl (ml/min) | Dosage Recommendation |
<30 | Reduce maintenance dose to 1/3 of the usual dose (either by administering the maintenance dose every 3 days or by giving 1/3 of the maintenance dose once daily) |
30-80 | Reduce the maintenance dose to half of the usual dose (either by administering the maintenance dose every 2 days or by giving half of the maintenance dose once daily). |
Reconstitution: Powder for solution for inj/infusion or oral solution: Reconstitute a vial labelled as containing 200 mg or 400 mg with 3.14 mL of sterile water for inj to prepare a 200 mg/3mL or 400 mg/3mL concentration, respectively. Rotate slowly to dissolve the powder. Do not shake. If foam develops, allow the solution to stand for 15 minutes. Further dilute the reconstituted solution with a suitable IV fluid for infusion (e.g. NaCl 0.9% solution, dextrose 5% inj). Refer to local detailed product guidelines for further compatible infusion fluids. Reconstituted solution may be injected directly, further diluted for IV infusion or peritoneal dialysis solution, or prepared for oral administration.
Incompatibility: Incompatible with aminoglycoside solution when used for inj or infusion. However, teicoplanin and aminoglycoside solutions are compatible in dialysis fluid and may be used for CAPD-related peritonitis.